Dulaglutide and Multiple Sclerosis: First GLP-1RA Trial Shows Walking Speed Improvements

A drug designed to control blood sugar just helped multiple sclerosis patients walk faster and grip better. That sentence alone should make every neurologist, neuroscientist, and MS patient pay attention.

The First GLP-1RA Trial in Multiple Sclerosis

On June 20, 2026, Neurology and Therapy published the results of a proof-of-concept randomized trial that nobody saw coming. Researchers at Comenius University in Bratislava, Slovakia, tested whether dulaglutide — a GLP-1 receptor agonist (GLP-1RA) typically prescribed for type 2 diabetes — could do anything for people living with relapsing-remitting multiple sclerosis (RRMS).

The answer, at least at the exploratory level, was yes.

The trial enrolled 28 patients with RRMS who were already stable on natalizumab, one of the most effective disease-modifying therapies for MS. Fifteen received adjunctive dulaglutide at 0.75 mg subcutaneously once weekly for 12 months. Thirteen served as controls, continuing natalizumab alone. The study was randomized, open-label, and single-center — small, but rigorously designed for a proof-of-concept.

What the Numbers Showed

The metabolic results were clean and expected. Dulaglutide significantly reduced body weight, BMI, body fat percentage, and visceral fat. Glucose tolerance improved, with reduced glucose area under the curve on oral glucose tolerance testing. No surprises there — these are well-documented effects of GLP-1RAs across dozens of clinical contexts.

The neurological results were where things got interesting.

Walking speed (Timed 25-Foot Walk): The dulaglutide group showed a statistically significant improvement compared to controls (group × time interaction: F1,26 = 9.4, p = 0.005). For MS patients, the T25FW is a critical functional measure — it directly tracks disability progression. An improvement here is clinically meaningful.

Manual dexterity (9-Hole Peg Test): The dulaglutide group improved on the non-dominant hand test (F1,26 = 4.7, p = 0.039). This measures fine motor coordination, which is often impaired in MS due to cerebellar and upper motor neuron lesions.

On the primary outcomes — plasma neurofilament light chain (NfL), a biomarker of neuroaxonal damage, and brain MRI volumetric measures — there were no significant between-group differences. This means dulaglutide did not demonstrably halt the underlying neurodegenerative process at the biological level, at least not within 12 months at this dose.

Safety was unremarkable. No adverse events were recorded in either group. No discontinuations occurred.

Why This Matters Beyond MS

This trial did not emerge in a vacuum. The idea that GLP-1 receptor agonists might protect the brain has been building for years, driven by three converging lines of evidence.

GLP-1 receptors are everywhere in the brain. A comprehensive review published in Biological Psychiatry on June 19, 2026 (Bashaw et al., University of Southern California) synthesized the evidence: GLP-1 receptors are widely expressed in the hippocampus and interconnected regions critical for learning and memory. The review described multiple mechanisms by which GLP-1R signaling can enhance brain function — direct action on hippocampal receptors after crossing the blood-brain barrier, improved central insulin sensitivity, vagus nerve activation, and reduced peripheral inflammation.

Animal models keep showing neuroprotective effects. In May 2026, researchers at Shanghai Jiao Tong University demonstrated that semaglutide ameliorated neuroinflammation and cognitive impairment in APP/PS1 mice, a standard Alzheimer’s disease model (Yuan et al., Molecular and Cellular Biochemistry). Earlier work showed liraglutide reducing amyloid-beta accumulation and inflammation in 5xFAD mice.

But human trials have been mixed. A landmark overview of randomized clinical trials published in Diabetes Research and Clinical Practice (July 2026, Mourtzos et al., Harvard/Beth Israel) concluded that while early-phase trials and neuroimaging studies suggest potential benefits on regional brain metabolism and selected cognitive domains, large randomized trials have generally failed to demonstrate consistent disease-modifying effects. The authors called for longer treatment duration, earlier intervention windows, and biomarker-guided patient stratification.

The dulaglutide-MS trial fits squarely into this picture: suggestive functional signals at the exploratory level, but no clear impact on hard biological endpoints. It is the first human randomized trial of a GLP-1RA in multiple sclerosis, and that alone makes it significant.

The Mechanism Nobody Fully Understands

Why would a diabetes drug improve walking speed in MS patients who are already on an effective disease-modifying therapy? Several hypotheses are in play.

First, GLP-1RAs have potent anti-inflammatory properties that extend well beyond glucose control. MS is fundamentally an inflammatory disease — the immune system attacks myelin, the insulating sheath around nerve fibers. If dulaglutide reduces central nervous system inflammation even modestly, it could improve conduction in partially demyelinated neurons, translating to better motor function.

Second, metabolic dysfunction is increasingly recognized as a contributor to MS disability. Many MS patients have impaired glucose tolerance, insulin resistance, or metabolic syndrome — conditions that worsen neuroinflammation and accelerate disability. By improving metabolic parameters (weight, body fat, visceral fat, glucose tolerance), dulaglutide may have created a more favorable internal environment for neural function.

Third, there is emerging evidence that GLP-1 signaling directly supports mitochondrial function and energy metabolism in neurons. If MS neurons are energy-starved due to demyelination-related metabolic stress, enhancing their energy supply could improve function even without repairing the myelin itself.

The Oria Take

This is a proof-of-concept study with 28 patients. It does not change clinical practice. It does not mean MS patients should rush to get dulaglutide prescriptions. But it does something arguably more important at this stage: it opens a door.

The peptide and peptide-adjacent drug space has been overwhelmingly focused on weight loss and metabolic disease. This trial is a reminder that GLP-1 receptor agonists have pharmacological effects far beyond appetite suppression. The brain is rich in GLP-1 receptors, and we are only beginning to understand what happens when we activate them therapeutically.

For the Oria community, this reinforces a core principle: the most interesting developments in peptide science often come from unexpected directions. A diabetes drug for MS. A gut hormone for Alzheimer’s. A weight loss peptide for neuroprotection. The underlying biology does not respect our clinical categories.

We will be watching for the larger, adequately powered trials the authors called for. Higher doses, longer follow-up, and more sophisticated biomarker endpoints could turn this exploratory signal into something definitive.

Evidence Grade: C+ (Proof-of-Concept) — Small sample (n=28), exploratory functional endpoints showed significance, but primary biomarker endpoints (NfL, MRI volumetry) were negative. Promising signal requiring larger replication. Registered as EudraCT 2019-003001-94.

Sources

Primary: Šiarnik P et al. “Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial.” Neurology and Therapy. June 20, 2026. PMID: 42321509.

GLP-1 Brain Signaling: Bashaw AG et al. “Glucagon-like peptide-1 signaling in learning and memory: evidence, mechanisms, and therapeutic implications.” Biological Psychiatry. June 19, 2026. PMID: 42320781.

Semaglutide in Alzheimer’s Model: Yuan Y et al. “Semaglutide ameliorates neuroinflammation and cognitive impairment in APP/PS1 mice.” Molecular and Cellular Biochemistry. May 13, 2026. PMID: 42126676.

GLP-1 Neuroprotection Overview: Mourtzos MA et al. “Repurposing GLP-1 receptor agonists and SGLT-2 inhibitors in neurodegeneration: Myth or reality?” Diabetes Research and Clinical Practice. July 2026. PMID: 42208664.

Liraglutide Cognitive Function: Liraglutide improves cognitive function by reducing amyloid-beta peptide accumulation and inhibiting inflammation in 5 × FAD mice. J Gerontol A Biol Sci Med Sci. January 2026. PMID: 41349262.

Medical Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or modifying any medication or supplement regimen. The research discussed is preliminary and should not be interpreted as clinical guidance. Oria BioStack provides science-based education about peptide research — not personalized medical recommendations.